Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: Milan Italy (1918)

Organization Overview

First Clinical Trial
2006
NCT00397072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fondazione IRCCS Istituto neurologico Carlo Besta | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Fondazione IRCCS Istituto Neurologico "Carlo Besta" | Fondazione IRCCS Istituto Neurologico Carlo Besta | Fondazione IRCCS Istituto Neurologico Carlo Besta di Milano | Fondazione IRCCS Istituto Neurologico C. Besta | Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy | Foundation IRCCS Neurologic Institute Carlo Besta

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Ataxia (Phase 2)

Cerebellar Ataxia (Phase 2)

Cluster Headache (Phase 3)

Friedreich Ataxia (Phase 2)

Ganglion Cysts (Phase 3)

Glioblastoma (Phase 2)

Headache (Phase 3)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Recurrence (Phase 1)

Sclerosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 21